Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).
1 finding from 1 review
Major bleeding · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in major bleeding compared with inpatient treatment (low certainty).
2 findings from 1 review
Major bleeding · people requiring treatment for chronic DVT
Chronic DVT ‐ antiplatelet agents plus BMP showed no clear difference in major bleeding compared with BMP plus placebo (moderate certainty).
1 finding from 1 review
Major bleeding · people requiring treatment for acute DVT
1 finding from 1 review
Major bleeding · people requiring treatment for chronic DVT
1 finding from 1 review
Major bleeding · adults with ALI
It is very uncertain whether ultrasound‐accelerated thrombolysis changes major bleeding compared with thrombolysis alone (very low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin started before changes major bleeding compared with after the surgical procedure (very low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
Higher‐dose heparin showed no clear difference in major bleeding compared with standard‐dose heparin (low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin changes major bleeding compared with pentasaccharide (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).
1 finding from 1 review
Major bleeding · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
It is very uncertain whether antithrombin changes major bleeding compared with no thromboprophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review